OTC Medicines

This past week, the House of Representatives adjourned for its annual August recess, although the House Democratic Leadership indicated that members would be called back sometime in August, should the Senate pass the Inflation Reduction Act of 2022.

When it comes to self-care solutions, pharmacists can be an overlooked resource. Today we speak with Dr. Wendy Mobley-Bukstein, Associate Professor of Pharmacy Practice at Drake University about how pharmacists are playing bigger and critical roles in the self-care ecosystem.

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

House and Senate negotiators are at odds over how to move forward with the FDA user fee reauthorization now that Senate HELP Committee Ranking Member, Senator Richard Burr (R-N.C.) is pushing a significantly pared-down version of the user fee reauthorization bill.

CHPA’s President and CEO, Scott Melville, today released a statement in response to news of HRA Pharma’s application to the U.S. Food and Drug Administration (FDA) for the first-ever over-the-counter (OTC) birth control pill in the United States.

Now that the House of Representatives and the Senate HELP Committee have passed their respective FDA user fee bills, House and Senate negotiators have been working to conference and reconcile differences in both bills.

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

Industry executives from Europe and beyond gathered June 7-8, in Madrid, Spain, for the annual meeting of the Association of the European Self-Care Industry (AESGP), its first annual meeting since 2019. Under the theme “supporting innovation in self-care during times of uncertainty,” speakers focused on the European context of environmental sustainability, trends shaping the future of the consumer healthcare business, and the outlook for changes to the EU’s pharmaceutical framework, among other topics.